The global cosmetovigilance market size is calculated at USD 12.26 billion in 2025 and is forecasted to reach around USD 18.35 billion by 2034, accelerating at a CAGR of 4.59% from 2025 to 2034. The Europe cosmetovigilance market size accounted for USD 4.63 billion in 2025 and is expanding at a CAGR of 4.61% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Cosmetovigilance Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Cosmetovigilance Market, by Service Type
8.1.1. Pre-marketing Services
8.1.1.1. Market Revenue and Forecast
8.1.2. Post-marketing Services
8.1.2.1. Market Revenue and Forecast
9.1. Cosmetovigilance Market, by Categories
9.1.1. Skincare
9.1.1.1. Market Revenue and Forecast
9.1.2. Makeup
9.1.2.1. Market Revenue and Forecast
9.1.3. Haircare
9.1.3.1. Market Revenue and Forecast
9.1.4. Perfumes and deodorants
9.1.4.1. Market Revenue and Forecast
9.1.5. Hair colorants
9.1.5.1. Market Revenue and Forecast
9.1.6. Others
9.1.6.1. Market Revenue and Forecast
10.1. Cosmetovigilance Market, by Phase Type
10.1.1. Pre-clinical
10.1.1.1. Market Revenue and Forecast
10.1.2. Phase I
10.1.2.1. Market Revenue and Forecast
10.1.3. Phase II
10.1.3.1. Market Revenue and Forecast
10.1.4. Phase III
10.1.4.1. Market Revenue and Forecast
10.1.5. Phase IV
10.1.5.1. Market Revenue and Forecast
11.1. Cosmetovigilance Market, by Service Provider
11.1.1. In-house
11.1.1.1. Market Revenue and Forecast
11.1.2. Contract Outsourcing
11.1.2.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Service Type
12.1.2. Market Revenue and Forecast, by Categories
12.1.3. Market Revenue and Forecast, by Phase Type
12.1.4. Market Revenue and Forecast, by Service Provider
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Service Type
12.1.5.2. Market Revenue and Forecast, by Categories
12.1.5.3. Market Revenue and Forecast, by Phase Type
12.1.5.4. Market Revenue and Forecast, by Service Provider
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Service Type
12.1.6.2. Market Revenue and Forecast, by Categories
12.1.6.3. Market Revenue and Forecast, by Phase Type
12.1.6.4. Market Revenue and Forecast, by Service Provider
12.2. Europe
12.2.1. Market Revenue and Forecast, by Service Type
12.2.2. Market Revenue and Forecast, by Categories
12.2.3. Market Revenue and Forecast, by Phase Type
12.2.4. Market Revenue and Forecast, by Service Provider
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Service Type
12.2.5.2. Market Revenue and Forecast, by Categories
12.2.5.3. Market Revenue and Forecast, by Phase Type
12.2.5.4. Market Revenue and Forecast, by Service Provider
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Service Type
12.2.6.2. Market Revenue and Forecast, by Categories
12.2.6.3. Market Revenue and Forecast, by Phase Type
12.2.6.4. Market Revenue and Forecast, by Service Provider
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Service Type
12.2.7.2. Market Revenue and Forecast, by Categories
12.2.7.3. Market Revenue and Forecast, by Phase Type
12.2.7.4. Market Revenue and Forecast, by Service Provider
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Service Type
12.2.8.2. Market Revenue and Forecast, by Categories
12.2.8.3. Market Revenue and Forecast, by Phase Type
12.2.8.4. Market Revenue and Forecast, by Service Provider
12.3. APAC
12.3.1. Market Revenue and Forecast, by Service Type
12.3.2. Market Revenue and Forecast, by Categories
12.3.3. Market Revenue and Forecast, by Phase Type
12.3.4. Market Revenue and Forecast, by Service Provider
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Service Type
12.3.5.2. Market Revenue and Forecast, by Categories
12.3.5.3. Market Revenue and Forecast, by Phase Type
12.3.5.4. Market Revenue and Forecast, by Service Provider
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Service Type
12.3.6.2. Market Revenue and Forecast, by Categories
12.3.6.3. Market Revenue and Forecast, by Phase Type
12.3.6.4. Market Revenue and Forecast, by Service Provider
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Service Type
12.3.7.2. Market Revenue and Forecast, by Categories
12.3.7.3. Market Revenue and Forecast, by Phase Type
12.3.7.4. Market Revenue and Forecast, by Service Provider
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Service Type
12.3.8.2. Market Revenue and Forecast, by Categories
12.3.8.3. Market Revenue and Forecast, by Phase Type
12.3.8.4. Market Revenue and Forecast, by Service Provider
12.4. MEA
12.4.1. Market Revenue and Forecast, by Service Type
12.4.2. Market Revenue and Forecast, by Categories
12.4.3. Market Revenue and Forecast, by Phase Type
12.4.4. Market Revenue and Forecast, by Service Provider
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Service Type
12.4.5.2. Market Revenue and Forecast, by Categories
12.4.5.3. Market Revenue and Forecast, by Phase Type
12.4.5.4. Market Revenue and Forecast, by Service Provider
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Service Type
12.4.6.2. Market Revenue and Forecast, by Categories
12.4.6.3. Market Revenue and Forecast, by Phase Type
12.4.6.4. Market Revenue and Forecast, by Service Provider
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Service Type
12.4.7.2. Market Revenue and Forecast, by Categories
12.4.7.3. Market Revenue and Forecast, by Phase Type
12.4.7.4. Market Revenue and Forecast, by Service Provider
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Service Type
12.4.8.2. Market Revenue and Forecast, by Categories
12.4.8.3. Market Revenue and Forecast, by Phase Type
12.4.8.4. Market Revenue and Forecast, by Service Provider
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Service Type
12.5.2. Market Revenue and Forecast, by Categories
12.5.3. Market Revenue and Forecast, by Phase Type
12.5.4. Market Revenue and Forecast, by Service Provider
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Service Type
12.5.5.2. Market Revenue and Forecast, by Categories
12.5.5.3. Market Revenue and Forecast, by Phase Type
12.5.5.4. Market Revenue and Forecast, by Service Provider
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Service Type
12.5.6.2. Market Revenue and Forecast, by Categories
12.5.6.3. Market Revenue and Forecast, by Phase Type
12.5.6.4. Market Revenue and Forecast, by Service Provider
13.1. Poseidon CRO
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. AxeRegel
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. PharSafer
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. AB Cube
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Aixial Group
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Di Renzo
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Pharmathen
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Skill Pharma
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. OC Vigilance
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Preclinical
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample